Siyan Zhan

Professor, MD. Ph.D
siyan-zhan@bjmu.edu.cn
Xueyuanlu 38., Haidian district, Beijing, China
Peking University

Personal profile

Positions and Honors:

1/2022-present Dean, School of Public Health, Peking University

3/2023-present Director, Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education

7/2018-present Director, Center for Clinical Epidemiology, Peking University Third Hospital

10/2019-present Director, Center for Intelligent Public Health, Institute for Artificial Intelligence, Peking University

5/2016-10/2023 Chair, Dept. of Epidemiology and Biostatistics, School of Public Health, Peking University

9/2013-present Director, Center of Postmarketing Safety Evaluation, PUHSC

2002-present Deputy Director, Peking University Center for Evidence-Based Medicine

Professional Memberships:

1.Fellow of the Faculty of Public Health (FPH)

2.Member of IEA

3.Member of ISPE

4.Chairman of China Pharmacoepidemiology Association, 2015-

5.Chairman of China Epidemiology Association, 2019-

6.Editor-in-Chief, Chinese Journal of Pharmacoepidemiology, 2015-

7.Deputy Editor-in-Chief, Chinese Journal of Epidemiology,2014-

Main research directions

1. Pharmacoepidemiology

2. Clinical Epidemiology and Evidence-based Medicine

Representative scientific research projects

1. Research on epidemiological methodologies of post-marketing active surveillance for vaccine safety driven by big data. National Natural Science Foundation(Key Program), 2024-2028

2. Construction and Implementation Study of the Active Vigilance Model for Vaccine Safety in China. BMGF-NSFC Joint Project on Regulatory Science,2024-2026

3. Pharmacovigilance real world research. Bill and Melinda Gates Foundation,2021-2025

4. Strategies and Empirical Study on identifying and controlling time-related bias in pharmacoepidemiology. National Natural Science Foundation, 2020-2023

5. Cohort consortium development for specific diseases of respiratory system. National key research and development program precision medicine. 2016-2020

6. Development and optimization of multi-view and multi-modal irrational prescription detection model for clinical big data. National Natural Science Foundation, 2016-2019

7. Methodology study of the active surveillance of adverse drug reaction based on common data model in MDR-TB patient. National Natural Science Foundation, 2015-2018

8. The active surveillance of ADR of cardiovascular treatment. Beijing Science and Technology Project. 2015-2019

9. Genome Epidemiology of anti-TB drug-induced liver injury in a Chinese cohort. National Natural Science Foundation (Key Program), 2011-2014

10. The impact of genetic predisposition of drug-metabolizing enzymes on anti-tuberculosis drugs-induced liver injury: A nested case-control study. National Natural Science Foundation, 2008-2010

10 representative papers

1. Liu Z, Li N, Liu G, Xu L, Dong Y, Meng R, Yang Y, Zhan S. No increased risk of intussusception after pentavalent rotavirus vaccination in China: a retrospective birth cohort using electronic health records of Ningbo city. Emerg Microbes Infect. 2023 Dec;12(2):2270062.

2. Xu L, He B, Sun Y, Li J, Shen P, Hu L, Liu G, Wang J, Duan L, Zhan S, Wang S. Incidence of Inflammatory Bowel Disease in Urban China: A Nationwide Population-based Study. Clin Gastroenterol Hepatol. 2023 Sep 1:S1542-3565(23)00662-6.

3. Zhao H, Zhuo L, Sun Y, Shen P, Lin H, Zhan S. Thiazolidinedione use and risk of Parkinson's disease in patients with type 2 diabetes mellitus. NPJ Parkinsons Dis. 2022 Oct 21;8(1):138.

4. Zhao H, Wei L, Li H, Zhang M, Cao B, Bian J, Zhan S. Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study. Lancet Infect Dis. 2021 Jun;21(6):847-857.

5. Sun Y, Pei Z, Zhao H, Li L, Hu Y, Zhang L, Wang L, Yang Y, Huang T, Zhan S; China Cohort Consortium study group. Data Resource Profile: China Cohort Consortium (CCC). Int J Epidemiol. 2020 Oct 1;49(5):1436-1436m.

6. Zhang C, Feng J, Wang S, Gao P, Xu L, Zhu J, Jia J, Liu L, Liu G, Wang J, Zhan S, Song C. Incidence of and trends in hip fracture among adults in urban China: A nationwide retrospective cohort study. PLoS Med. 2020 Aug 6;17(8):e1003180.

7. Xu L, Chen L, Wang S, Feng J, Liu L, Liu G, Wang J, Zhan S, Gao P, Fan D. Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study. J Neurol Neurosurg Psychiatry. 2020 May;91(5):520-525.

8. Chen R, Wang J, Zhang Y, Tang S, Zhan S. Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity[J]. Arch Toxicol, 2015,89(6):883-897.

9. Sun F, Yu K, Wu S, Zhang Y, Yang Z, Shi L, Ji L, Zhan S. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis[J]. Diabetes Res Clin Pract, 2012,98(3):386-395.

10. Zhan S, Ho SC. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr. 2005 Feb;81(2):397-408.